Results 121 to 130 of about 70,436 (267)

Current Cell/Organoid and Animal Models for Primary Sclerosing Cholangitis

Portal Hypertension &Cirrhosis, EarlyView.
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with limited therapeutic options and a marked risk of progression to biliary fibrosis, cirrhosis, and malignancy. Progress in PSC research has been hindered by the lack of models that faithfully recapitulate the complex biliary microenvironment and disease heterogeneity ...
Qigu Yao, Sheng Cheng, Qiaoling Pan, Jiong Yu, Hongcui Cao   +4 more
wiley   +1 more source

Application and Research Progress of Self-Assembling Protein Nanoparticles in Vaccine Development. [PDF]

Int J Mol Sci
Zhang Y, Ru Y, Li X, Wang G, Hu Y, Jian Y, Ma L.   +6 more
europepmc   +1 more source

When Fat Goes Astray: Your Liver and Pancreas Get Into Trouble

Portal Hypertension &Cirrhosis, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) and intrapancreatic fat deposition (IPFD) are both common manifestations of ectopic fat accumulation. Although they share multiple risk factors, they also show notable differences in pathological features, standardization of diagnosis, and research maturity.
Yuying Chen, Li Ding, Shan Zhao, Weihong Wang, Jing Zhong, Qiang Yan   +5 more
wiley   +1 more source

Therapeutic hepatitis B vaccine employing DNA prime - MVA boost scheme requires additional priming with recombinant HBsAg to elicit an adequate antibody response. [PDF]

Front Immunol
Kerth HA, Kächele M, Müller N, Singh S, Tulessin M, Sacherl J, Ates Öz E, Su J, Bester R, Miko S, Steiger K, Mogler C, Busch DH, Wettengel JM, Protzer U, Kosinska AD.   +15 more
europepmc   +1 more source

Advances in Viral Markers for Predicting Functional Cure of Chronic Hepatitis B

Portal Hypertension &Cirrhosis, EarlyView.
Functional cure, defined as sustained hepatitis B surface antigen (HBsAg) loss, is achieved by only a minority of patients with chronic hepatitis B (CHB); early identification of likely responders may improve cure rates and reduce costs. However, responses to antiviral therapy vary considerably, necessitating reliable hepatitis B virus (HBV) viral ...
Xinrong Lu, Xin Yang, Qishui Ou, Zhen Xun   +3 more
wiley   +1 more source

Antiviral efficacy of LNP-delivered IFN-α14-ApoAI mRNA for chronic hepatitis B. [PDF]

J Virus Erad
Yang Q, Li Q, Cao J, Zhao C, Lu M, Sun S, Chen M, Chen C, Huang Y, Tao S, Chen L.   +10 more
europepmc   +1 more source

Radiotherapy and Immunotherapy In Hepatocellular Carcinoma: Priming the Tumor Immune Microenvironment From Bench To Bedside

Precision Radiation Oncology, EarlyView.
The dual immunomodulatory network of radiotherapy in hepatocellular carcinoma. Radiotherapy initiates its effects by inducing immunogenic cell death and DNA double‐strand breaks. Immune Activation: Cytosolic DNA from damaged cells activates the cGAS‐STING pathway, triggering IRF3/NF‐κB‐mediated type I interferon production. This enhances dendritic cell
Zhigang Fu, Yang Zhang, Zuomin Wang, Zongjuan Li, Shisuo Du   +4 more
wiley   +1 more source

Detection of Vaccine-Derived Spike Protein Associated with Immune Cell Infiltration in the Heart and Liver: A Report of Two Cases. [PDF]

Cells
Mörz M, Donzelli A, Clancy RL, Sano S, Fukushima M, Polykretis P.   +5 more
europepmc   +1 more source

Disease Progression Mathematical Modeling With a Case Study on Hepatitis B Virus Infection

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 420-434, March 2025.
ABSTRACT Chronic Hepatitis B presents a significant health and socioeconomic burden. The risk of hepatocellular carcinoma remains elevated although treatments are available. Achieving an optimal treatment regimen necessitates a deep comprehension of the dynamic relationship between the virus and its host across disease states.
Clémence Boivin‐Champeaux, Nieves Velez de Mendizabal, Aksana Jones, Scott Balsitis, Stephan Schmidt, Justin S. Feigelman, Francine Johansson Azeredo   +6 more
wiley   +1 more source

CD72 downregulation is associated with increased CD5+ B cell proliferation and IL-10 production via ERK/Syk signaling in chronic HBV infection-associated liver disease. [PDF]

Virus Res
Li B, Zhao L, Zhu Q, Xie S.
europepmc   +1 more source